Marizyme, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MRZM research report →
Price Chart
About the company
Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics.
- CEO
- David L. Barthel
- IPO
- 2010
- Employees
- 13
- HQ
- Jupiter, FL, US
Get TickerSpark's AI analysis on MRZM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $39.54K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.06
- P/B
- -0.00
- EV/EBITDA
- -0.37
- Div Yield
- 0.00%
- Gross Margin
- 36.99%
- Op Margin
- -5278.10%
- Net Margin
- -10767.77%
- ROE
- -1089.84%
- ROIC
- -175.14%
Latest fiscal year · YoY change
- Revenue
- $645.81K+176.6%
- Gross Profit
- $238.91K+33.3%
- Op Income
- $-34,086,516
- Net Income
- $-69,539,336-82.2%
- EPS
- $-1.53-62.8%
- OCF Growth
- +56.8%
- FCF Growth
- +56.8%
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.86
- RSI (14)
- 52
- Avg Volume
- 1.82K
No earnings-call transcripts are available for MRZM yet.
- Free Float
- 65.0%
- Shares Outstanding
- 131.79M
- Float Shares
- 85.64M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 21, 23 | Braeden Lichti | other | 3,815,294 |
| Dec 21, 23 | Braeden Lichti | other | 2 |
| Jun 29, 23 | Lichti Braeden | sell | 106,327 |
| Jul 7, 23 | Lichti Braeden | sell | 97,000 |
| Aug 29, 23 | Lichti Braeden | sell | 105,000 |
| Jun 29, 23 | Lichti Braeden | buy | 106,327 |
| Jul 7, 23 | Lichti Braeden | buy | 97,000 |
| Aug 29, 23 | Lichti Braeden | buy | 105,000 |
| Apr 14, 23 | Dhaduk Vithalbhai D | other | 1,063,938 |
| Apr 14, 23 | Dhaduk Vithalbhai D | other | 1,063,938 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MRZM coverage
Recent articles, reports, and earnings notes.
No research on MRZM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MRZM report →Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
globenewswire.com · Apr 16
Marizyme CEO Delivers Business Update
globenewswire.com · Oct 23
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™
globenewswire.com · Oct 6
U.S. IPO Weekly Recap: The IPO Market's Micro-Cap Run Continues With 2 Small Healthcare Deals
seekingalpha.com · Feb 18
Marizyme is Pleased to Announce the Appointment of David Barthel as CEO
globenewswire.com · Nov 16
Marizyme, Inc. Issues Letter to Shareholders
prnewswire.com · Mar 31
Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera
prnewswire.com · Mar 4
Marizyme, Inc. Strengthens Senior Management Team with Two Appointments: Roger Schaller EVP, Commercial Operations and Amy Chandler, EVP, Regulatory Affairs and Quality Management Systems
prnewswire.com · Feb 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.